| | Study | Patient group | Participant (M/W) | Treatment measure | Duration | Outcomes | | Control | Treatment | Control | Treatment |
| | Chen 2019 | T2DM&CHD 128 | 64 (29/35) | 64 (31/33) | CT | Yanshi Yixin decoction+CT | 3 m | BG, BL, SAA, MMP-9, TBIL | | Cheng 2019 | T2DM&CHD 118 | 60 | 58 | CT | Supplemented Yuye decoction+CT | 3 m | BG, BL, IM, SOD, MDA, GSH-Px, 8-ios-PGF2a | | Feng 2020 | T2DM&CHD 130 | 65 (33/32) | 65 (35/30) | CT | Shexiang Baoxin Pill+CT | 3 m | BL | | Gao 2018 | T2DM&CHD 100 | 50 (27/23) | 50 (24/26) | CT | Shengmai powder+CT | 2 m | BG, BL, FGF-21, Ghrelin | | Li 2008 | DM&CHD 100 | 50 (33/17) | 50 (32/18) | CT | Jiangtang Shengmai decoction+CT | 2 m | BG, BL, HI | | Li 2021 | T2DM&CHD 286 | 143 (75/68) | 143 (76/67) | CT | Tongxinluo capsule+CT | 3 m | CF, BL, BG | | Liu 2008 | T2DM&CHD 260 | 130 (95/35) | 130 (89/41) | CT | Xinshu pill+CT | 2 m | BG, IM, DD, LFTs, KFTs | | Liu 2019 | T2DM&CHD 108 | 54 (29/25) | 54 (28/26) | CT | Shexiang Yangxin powder+CT | 3 m | BG, BL, HI | | Ni 2010 | T2DM&CHD 173 | 45 (21/24) | 128 (55/73) | CT | Qizhi Jiangtang capsule+CT | 2 m | BG, dynamic ECG | | Ning 2017 | T2DM&CHD 150 | 75 (34/41) | 75 (35/40) | CT | Yindan Xinnaotong soft capsule+CT | 3 m | HI, angina frequency | | Pan 2019 | T2DM&SAP 120 | 60 (29/31) | 60 (28/32) | CT | Yiqi Yangyin Huoxue decoction_CT | 3 m | BG, BL, CRP, Hcy, UMA | | Qian 2017 | DM&ACS 294 | 147 (97/50) | 147 (102/45) | CT | Xinyue capsule+CT | 6 m | CE, BG, NT-proBNP, CK-MB | | Qian 2018 | T2DM&CHD 150 | 75 (43/32) | 75 (45/30) | CT | Tongguan Huoxue decoction+Naoxintong capsule+CT | 3 m | BG, BL, HMGB1, Omentin-1 | | Ren 2020 | T2DM&CHD 320 | 160 (85/75) | 160 (78/82) | CT | Tongguan Huoxue decoction+Naoxintong capsule+CT | 3 m | CF, BG | | Shi 2020 | T2DM&CHD 120 | 60 (16/44) | 60 (18/42) | CT | Yindan Xinnaotong soft capsule+CT | 3 m | Angina frequency, BL | | Tao 2017 | T2DM&CHD 118 | 55 (33/22) | 63 (43/20) | CT | Hedan pill+CT | 6 m | BL, IM, SOD, MDA, NO | | Zhang 2015 | T2DM&CHD 102 | 51 (30/21) | 51 (28/23) | CT | Shuxin Huoxue decoction+CT | 2 m | BL, IM, HI | | Zhang 2019 | T2DM&SAP 179 | 81 (43/38) | 98 (49/49) | CT | Yiqi Yangyin decoction+CT | 3 m | CE, BG, BL, HI, IM | | Zhang 2020 | DM&CHD 134 | 67 (36/31) | 67 (34/33) | CT | Xuezhikang+CT | | BG, BL, HI, IM, CF | | Zhao 2007 | T2DM&CHD 591 | 285 (198/87) | 306 (226/80) | Placebo+CT | Xuezhikang+CT | 4 y | ACM, CE, BL |
|
|
